Additive effects of the Rho kinase inhibitor Y-27632 and vardenafil on relaxation of the corpus cavernosum tissue of patients with erectile dysfunction and clinical phosphodiesterase type 5 inhibitor failure

被引:17
|
作者
Uvin, Pieter [1 ,2 ,3 ]
Albersen, Maarten [1 ,3 ]
Bollen, Ine [4 ]
Falter, Maarten [4 ]
Weyne, Emmanuel [1 ,3 ]
Linsen, Loes [5 ]
Tinel, Hanna [6 ,7 ]
Sandner, Peter [6 ,7 ]
Bivalacqua, Trinity J. [8 ]
De Ridder, Dirk J. M. K. [1 ,3 ]
Van der Aa, Frank [1 ,3 ]
Brone, Bert [4 ]
Van Renterghem, Koenraad [1 ,2 ]
机构
[1] Univ Hosp Leuven, Dept Urol, Herestr 49, B-3000 Leuven, Belgium
[2] Hasselt Univ, Jessa Hosp, Dept Urol, Hasselt, Belgium
[3] Katholieke Univ Leuven, Dept Dev & Regenerat, Cluster Organ Syst, Fac Med,Grp Biomed Sci, Leuven, Belgium
[4] Univ Hasselt, Physiol Grp, Hasselt, Belgium
[5] Univ Biobank Limburg, Jessa Hosp, Hasselt, Belgium
[6] Bayer HealthCare, Global Drug Discovery, Wuppertal, Germany
[7] Hannover Med Sch, Inst Pharmacol, Hannover, Germany
[8] Johns Hopkins Med Inst, Dept Urol, James Buchanan Brady Urol Inst, Baltimore, MD 21205 USA
关键词
Rho kinase inhibitor; corpus cavernosum; erectile dysfunction; Rho/Rho associated protein kinase (ROCK) pathway; Y-27632; phosphodiesterase type 5 inhibitor; NERVE INJURY; RATS; ANTAGONISM; THERAPIES; MECHANISM; ISCHEMIA; FASUDIL; SPASM; PENIS;
D O I
10.1111/bju.13691
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To evaluate the expression of the Rho/Rho-associated protein kinase (ROCK) pathway in the corpus cavernosum of patients with severe erectile dysfunction (ED) compared with healthy human corpus cavernosum, and to test the functional effects of two Rho kinase inhibitors (RKIs) on erectile tissue of patients with severe ED, which did not respond to phosphodiesterase type 5 inhibitors (PDE5Is). Patients and Methods Human corpus cavernosum samples were obtained after consent from men undergoing penile prosthesis implantation (n = 7 for organ bath experiments, n = 17 for quantitative PCR [qPCR]). Potent control subjects (n = 5) underwent penile needle biopsy. qPCR was performed for the expression of RhoA and ROCK subtypes 1 and 2. Immunohistochemistry staining against ROCK and alpha smooth muscle actin (alpha SMA) was performed on the corpus cavernosum of patients with ED. Tissue strips were precontracted with phenylephrine and incubated with 1 mu M of the PDE5I vardenafil or with DMSO (control). Subsequently, increasing concentrations of the RKIs azaindole or Y-27632 were added, and relaxation of tissue was quantified. Results The expression of ROCK1 was unchanged (P > 0.05), while ROCK2 (P < 0.05) was significantly upregulated in patients with ED compared with controls. ROCK1 and ROCK2 protein colocalized with alpha SMA, confirming the presence of this kinase in cavernous smooth muscle cells and/or myofibroblasts. After incubation with DMSO, 10 mu M azaindole and 10 mu M Y-27632 relaxed precontracted tissues with 49.5 +/- 7.42% (P = 0.1470 when compared with vehicle) and 85.9 +/- 10.3% (P = 0.0016 when compared with vehicle), respectively. Additive effects on relaxation of human corpus cavernosum were seen after preincubation with 1 mu M vardenafil. Conclusion The RKI Y-27632 causes a significant relaxation of corpus cavernosum in tissue strips of patients with severe ED. The additive effect of vardenafil and Y-27632 shows that a combined inhibition of Rho-kinase and phosphodiesterase type 5 could be a promising orally administered treatment for severe ED.
引用
收藏
页码:325 / 332
页数:8
相关论文
共 33 条
  • [21] Effects of sildenafil, a type-5 cGMP phosphodiesterase inhibitor, and papaverine on cyclic GMP and cyclic AMP levels in the rabbit corpus cavernosum in vitro
    Jeremy, JY
    Ballard, SA
    Naylor, AM
    Miller, MAW
    Angelini, GD
    BRITISH JOURNAL OF UROLOGY, 1997, 79 (06): : 958 - 963
  • [22] Factors associated with ejaculatory and orgasmic dysfunction in men with erectile dysfunction: analysis of clinical trials involving the phosphodiesterase type 5 inhibitor tadalafil
    Paduch, Darius A.
    Bolyakov, Alexander
    Beardsworth, Anthony
    Watts, Steven D.
    BJU INTERNATIONAL, 2012, 109 (07) : 1060 - 1067
  • [23] Sildenafil, a type-5 CGMP phosphodiesterase inhibitor, specifically amplifies endogenous cGMP-dependent relaxation in rabbit corpus cavernosum smooth muscle in vitro
    Chuang, AT
    Strauss, JD
    Murphy, RA
    Steers, WD
    JOURNAL OF UROLOGY, 1998, 160 (01) : 257 - 261
  • [24] Phosphodiesterase type 5 inhibitor therapy: identifying and exploring what attributes matter more to clinicians and patients in the management of erectile dysfunction
    Axilrod, Andrew C.
    CURRENT MEDICAL RESEARCH AND OPINION, 2007, 23 (12) : 3189 - 3198
  • [25] Synergistic effects of Rho kinase inhibitor Y-27632 and Noggin overexpression on the proliferation and neuron-like cell differentiation of stem cells derived from human exfoliated deciduous teeth
    Yang, Si
    Xin, Cuijuan
    Zhang, Bo
    Zhang, Hongbo
    Hao, Yunpeng
    IUBMB LIFE, 2020, 72 (04) : 665 - 676
  • [26] Risk of Melanoma With Phosphodiesterase Type 5 Inhibitor Use Among Patients With Erectile Dysfunction, Pulmonary Hypertension, and Lower Urinary Tract Symptoms
    Shkolyar, Eugene
    Li, Shufeng
    Tang, Jean
    Eisenberg, Michael L.
    JOURNAL OF SEXUAL MEDICINE, 2018, 15 (07) : 982 - 989
  • [27] Phosphodiesterase Type 5 Inhibitor Treatment for Erectile Dysfunction in Patients with End-Stage Renal Disease Receiving Dialysis or After Renal Transplantation
    Lasaponara, Fedele
    Sedigh, Omid
    Pasquale, Giovanni
    Bosio, Andrea
    Rolle, Luigi
    Ceruti, Carlo
    Timpano, Massimiliano
    Negro, Carlo Luigi Augusto
    Paradiso, Matteo
    Abbona, Annamaria
    Segoloni, Giuseppe Paolo
    Fontana, Dario
    JOURNAL OF SEXUAL MEDICINE, 2013, 10 (11) : 2798 - 2814
  • [28] Combination of BAY 60-4552 and Vardenafil Exerts Proerectile Facilitator Effects in Rats With Cavernous Nerve Injury: A Proof of Concept Study for the Treatment of Phosphodiesterase Type 5 Inhibitor Failure
    Oudot, Alexandra
    Behr-Roussel, Delphine
    Poirier, Sarah
    Sandner, Peter
    Bernabe, Jacques
    Alexandre, Laurent
    Giuliano, Francois
    EUROPEAN UROLOGY, 2011, 60 (05) : 1020 - 1026
  • [29] Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study
    Y S Shim
    C-U Pae
    K J Cho
    S W Kim
    J C Kim
    J S Koh
    International Journal of Impotence Research, 2014, 26 : 76 - 80
  • [30] Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study
    Shim, Y. S.
    Pae, C-U
    Cho, K. J.
    Kim, S. W.
    Kim, J. C.
    Koh, J. S.
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2014, 26 (02) : 76 - 80